Skip to content
Biodatica
Start free

Sarcoma Alliance for Research through Collaboration

Washington D.C., District of Columbia

OncologyPhase II
Compare Sign in to watch

What changed

Study registered, no phase assigned: Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

6w agoTrial registeredJun 4, 2026Source filing (opens the source filing in a new tab)

Momentum

85no change

Momentum 85 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,843 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Oct 9, 2024

    Neurofibromatosis 1, Nerve Sheath Neoplasms · RECRUITING · sponsor: National Cancer Institute (NCI) · Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

    ClinicalTrials.gov · NCT06222203 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Oct 2, 2019

    Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1 · COMPLETED · sponsor: Sarcoma Alliance for Research through Collaboration · SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

    ClinicalTrials.gov · NCT03433183 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Jan 7, 2016

    Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) · ACTIVE_NOT_RECRUITING · sponsor: National Cancer Institute (NCI) · MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

    ClinicalTrials.gov · NCT02407405 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources